PhDs are trained to build the future, so why is their funding strategy stuck in a pre-programmed loop?
It’s a peculiar irony that PhDs — careers built on questioning everything — often become the most unquestioning sheep the moment they enter the startup ecosystem. Despite careers built on breaking down arguments, research-based founders often accept that venture capital funding is the only valid pathway to success.
Yet they dismiss the growing pool of non-dilutive global capital, which often carries significant advantages for research-based ventures, even beyond initial venture capital sources.
The reasoning is simple: non-dilutive funding is cheap, strategic and can be a competitive advantage to stack future rounds of funding. This is particularly relevant to research-based ventures in a pre-regulatory clearance or non-commercial phase, which, in many cases, are too early for all but very specialized VC funds. Founders who win are often those who exhaust non-dilutive options first. Government grants can also signal to subsequent investors that their deep technology has passed rigorous external review, and thereby building a credible foundation for future rounds.
I recently advised a US-based founder who was ready to give away 20% equity to a high profile venture capital firm just to fund a basic pilot. When I asked why he hadn’t touched the millions in available global R&D grants or foundation money, he looked at me like I’d spoken a dead language. Was it really too daunting?
Non-dilutive as part of the capital stack
If this founder were a little more patient and curious, his preferred funding strategy might follow this trajectory:
non-dilutive → angels/family offices → VC, with each layer de-risking the next.
To illustrate, here is how a potential capital stacking strategy and sequencing might work:
Layer 1 — Non-dilutive (pre-regulatory proof points):
- Zero equity. Funds feasibility and proof-of-concept
- External validation signal that de-risks all subsequent rounds
- Might even get some cloud credits: AWS Activate + Google for Startups + Microsoft for Startups. $800K+ in infrastructure at zero dilution. You can apply to all three.
Layer 2 — Angels and specialist funds (bridge to regulatory milestone):
- Deep tech angels often tolerate 7–10 year timelines while generalist VCs do not. Choose them carefully.
- Checks of $250K–$2M provide a bridge to regulatory clearance
- Angels with domain expertise or regulatory connections can further advance a start-up beyond the money
- Having some non-dilutive capital (Layer 1) supports your early de-risking proposition to these investors.
Layer 3 — Deep tech VC (post-regulatory de-risking):
- Global megafunds often actively co-invest alongside government funds: for example, BpiFrance, UK British Patient Capital, Singapore co-investment scheme
- Grant history becomes a due diligence asset by signaling regulatory readiness before the VC enters the picture.
- Certain VC investors now explicitly evaluate regulatory readiness and data ownership at late-stage and pre-IPO rounds
- Active mega funds such as Flagship Pioneering $14B, Lux Capital $7B, DCVC $4B, and The Engine (MIT) $1B are indicative.
Understanding the Regulatory Angle for Deep Tech specifically
In short, each grant funds a regulatory milestone that would otherwise require dilutive capital. Getting that sorted first provides leverage to founders, where each layer de-risks the next. In this sense, the stack is a regulatory roadmap, not just a funding strategy.
A few examples include of non-dilutive capital melded with regulatory access:
- NSF SBIR funds IND-enabling studies
- Singapore’s 30-day clinical review pathway generates Phase I data
- EIC Transition grant funds lab-to-market translation
- Each layer derisks the next; in this sense, the stack is a regulatory roadmap, not just a funding strategy.
Ginkgo Bioworks received a $15M DARPA grant that didn’t just fund the science, but signaled to every subsequent investor that the technology had already cleared rigorous external review. The company went on the raise $290M in venture capital, and a $17.5B SPAC merger in the public markets.
Global Scale of the opportunity
As I’ve noted in this space, the investor opportunity is global. Here are a few sources to investigate, if your venture is in the market.
- Total US SBIR/STTR across all 11 federal agencies: $6.3B (per the SBA Annual Report); most founders think it’s $2.5B
- EU EIC 2026 work program: €1.4B committed to deep tech
- MENA sovereign Vision programs: $5B+ (Qatar $2.5B Digital Agenda + Saudi Vision 2030)
- Over the last decade EU Framework Programs provided €12B in direct grants to startups, attracted €70B in VC, with a collective valuation of €520B
This is the tip of the iceberg. The full regional breakdown — US, EU, MENA, Singapore, South Korea, India, and Latin America — is here »» LINK
ONE ACTION
Take your last grant rejection/approval, or your current research abstract, and rewrite it in 100 words for a non-scientist program officer at NSF, EIC, or your national science agency.
If the commercial and societal impact isn’t obvious in those 100 words, your non-dilutive fit isn’t a funding problem. It’s a translation problem.
CODA
Philip K. Dick spent a career asking whether something that looks real is real. Investors ask the same question about founders. The Voigt-Kampff test for your pitch isn’t your IP. It’s your empathy for the problem you’re solving..